SCHEMBL24155477

SCHEMBL24155477

c1ccc(Oc2ncc(-c3cn4ccnc4cn3)cn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGDS O60760 7/20 0.42
FYN P06241 4/20 0.41
TGFBR1 P36897 1/20 0.36
EGFR P00533 1/20 0.35
BTK Q06187 1/20 0.35
CHEK1 O14757 4/20 0.35
CHEK2 O96017 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 2/20 0.34
MAP4K4 O95819 1/20 0.34
CSF1R P07333 1/20 0.34
PRKACA P17612 1/20 0.34
KDR P35968 1/20 0.34
CDK8 P49336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24155867 0.87 EGFR (0.41) MEN1KMT2AHPGDSEGFRBTK
SCHEMBL21995639 0.82 MEN1 (0.52) MEN1NPC1GAARAB9AKMT2A
SCHEMBL24156328 0.82 ALOX5AP (0.35) MEN1NPC1RAB9AKMT2ATGFBR1
SCHEMBL1542371 0.81 CHEK1 (0.49) NPC1RAB9AKMT2ASMN1; SMN2FYN
SCHEMBL24155451 0.77 MEN1 (0.49) MEN1NPC1GAARAB9AKMT2A
SCHEMBL22044431 0.77 KDR (0.55) MEN1NPC1GAARAB9AKMT2A
SCHEMBL24155657 0.75 DYRK1A (0.55) MEN1NPC1GAARAB9AKMT2A
SCHEMBL24155656 0.74 CDK8 (0.63) MEN1NPC1GAARAB9AKMT2A
SCHEMBL24155858 0.72 DYRK1A (0.46) MEN1NPC1GAARAB9AKMT2A
SCHEMBL21644144 0.71 DYRK1A (0.59) MEN1KMT2AFYNTGFBR1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B MEN1 450/4885NPC1 1298/4885GAA 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.